Actively Recruiting
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Led by Regeneron Pharmaceuticals · Updated on 2026-05-13
220
Participants Needed
50
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
CONDITIONS
Official Title
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female participants aged 18 years or older
- Histologically or cytologically confirmed advanced serous or endometrioid ovarian cancer (all grades), primary peritoneal cancer, or fallopian tube cancer
- Excludes clear cell, mucinous, and carcinosarcoma subtypes
- Disease progression on prior therapy documented by imaging
- At least one measurable lesion not previously irradiated, measurable by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate organ and bone marrow function as defined in the protocol
- Platinum-resistant ovarian cancer as defined in the protocol
You will not qualify if you...
- Major surgery or serious injury within 4 weeks before starting the study treatment
- Known allergic or severe reactions to antibody treatments, doxorubicin, or study drug components
- Another active or progressing cancer requiring treatment as defined in the protocol
- Untreated or active central nervous system metastases or carcinomatous meningitis
- Uncontrolled infections including HIV, hepatitis B or C, or immunodeficiency
- Moderate to large ascites as described in the protocol
- Bowel obstruction within last 3 months or current need for feeding through IV nutrition
- Other protocol-defined exclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 50 locations
1
The University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Actively Recruiting
2
UC San Diego Health
La Jolla, California, United States, 92037
Actively Recruiting
3
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048
Actively Recruiting
4
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224
Actively Recruiting
5
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136
Actively Recruiting
6
Advent Health Cancer Institute
Orlando, Florida, United States, 32804
Actively Recruiting
7
Tampa General Hospital Cancer Institute
Tampa, Florida, United States, 33606
Actively Recruiting
8
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
9
The University of Kansas Cancer Center
Westwood, Kansas, United States, 66205
Actively Recruiting
10
Norton Cancer Institute, St. Matthews Clinic
Louisville, Kentucky, United States, 40207
Actively Recruiting
11
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
12
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Actively Recruiting
13
The Ohio State University Comprehensive Cancer Center
Hilliard, Ohio, United States, 43026
Actively Recruiting
14
Providence Cancer Institute
Portland, Oregon, United States, 97213
Actively Recruiting
15
West Penn Hospital of Allegheny Health Network
Pittsburgh, Pennsylvania, United States, 15224
Actively Recruiting
16
Avera Cancer Institute Sioux Falls
Sioux Falls, South Dakota, United States, 57105
Actively Recruiting
17
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
18
Swedish Cancer Institute
Seattle, Washington, United States, 98104
Actively Recruiting
19
University of Wisconsin
Madison, Wisconsin, United States, 53792
Actively Recruiting
20
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
21
Research Institute - McGill University Health Centre
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
22
Centre Hospitalier Universitaire (CHU) de Quebec - Universite Laval
Québec, Canada, G1J 0J9
Actively Recruiting
23
National Cancer Center
Gyeonggi-do, Gyeonggi-do, South Korea, 10408
Actively Recruiting
24
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620
Actively Recruiting
25
Gachon University Gil Medical Center
Incheon, Seoul, South Korea, 21565
Actively Recruiting
26
Keimyung University Dongsan Hospital
Daegu, South Korea, 42601
Actively Recruiting
27
Severance Hospital Yonsei University Health System
Seoul, South Korea, 03722
Actively Recruiting
28
Asan Medical Center, Univ. of Ulsan
Seoul, South Korea, 05505
Actively Recruiting
29
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
30
Gangnam Severance Hospital
Seoul, South Korea, 135-720
Actively Recruiting
31
Seoul National University Hospital
Seoul, South Korea, 3080
Actively Recruiting
32
Korea University Guro Hospital
Seoul, South Korea, 8308
Actively Recruiting
33
Changhua Christian Hospital
Changhua, Changhua City, Taiwan, 500
Actively Recruiting
34
Chi Mei Medical Center
Tainan, Taiwan, 71004
Actively Recruiting
35
Mackay Memorial Hospital
Taipei, Taiwan, 10449
Actively Recruiting
36
National Taiwan University Hospital
Taipei, Taiwan, 106
Actively Recruiting
37
Taipei Veterans General Hospital
Taipei, Taiwan, 11211
Actively Recruiting
38
Tri-Service General Hospital
Taipei, Taiwan, 114202
Actively Recruiting
39
Taipei Municipal Wan Fang Hospital
Taipei, Taiwan, 116
Actively Recruiting
40
Medicalpark Seyhan Hospital
Seyhan, Adana, Turkey (Türkiye), 01140
Actively Recruiting
41
Hacettepe University
Altındağ, Ankara, Turkey (Türkiye), 06240
Actively Recruiting
42
Medipol University Hospital
Istanbul, Bagcilar, Turkey (Türkiye), 34284
Actively Recruiting
43
Gaziantep Medicalpoint Hospital
Gaziantep, Sehitkamil, Turkey (Türkiye), 27584
Actively Recruiting
44
Baskent University
Adana, Turkey (Türkiye), 01123
Actively Recruiting
45
Sbu Doctor Abdurrahman Yurtaslan Ankara Onkoloji Suam
Ankara, Turkey (Türkiye), 06100
Actively Recruiting
46
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye), 06200
Actively Recruiting
47
Memorial Ankara Hospital
Ankara, Turkey (Türkiye), 0906520
Actively Recruiting
48
Cerrahpasa Medical Faculty At Istanbul University Cerrahpasa
Istanbul, Turkey (Türkiye), 34450
Actively Recruiting
49
Izmir Ekonomi Universitesi (IEU) Medical Point Izmir Hastanesi (Izmir Economy University Medical Point Izmir Hospital)
Izmir, Turkey (Türkiye), 35575
Actively Recruiting
50
Sakarya University - Education and Research Hospital
Sakarya, Turkey (Türkiye), 54290
Actively Recruiting
Research Team
C
Clinical Trials Administrator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here